RATIONALE: Severe asthma (SA) patients have a higher prevalence of comorbid upper airway diseases (UAD) which is associated with difficulty in achieving asthma control, reduced quality of life (QoL), and higher risk of exacerbation. Mepolizumab treatment improves asthma control, QoL and reduces exacerbations in SA patients; this analysis evaluates the efficacy in SA patients with co-morbid UAD. METHODS: A meta-analysis was conducted in SA patients from the mepolizumab phase 2b/3 clinical program (DREAM, MENSA, SIRIUS, and MUSCA) and investigated patients with self-reported history of comorbid UAD (allergic rhinitis, sinusitis, or nasal polyposis). Mepolizumab's effect on ACQ, SGRQ, and exacerbations, as compared to placebo in the SA population with and without comorbid UAD. RESULTS: Fifty-nine percent reported at least one upper airway comorbidity, with allergic rhinitis being the most frequent. In SA patients with comorbid UAD and treated with mepolizumab there was a 0.35 (95% CI 0.23, 0.48) improvement in ACQ score, a 7.5 point improvement in SGRQ (95%CI 5.2, 9.8) and a 51% reduction in exacerbations (RR 5 0.49; 95%CI 0.41, 0.58) as compared to placebo. In SA patients without comorbid UAD there was a 0.29 (95% CI 0.14, 0.44) improvement in ACQ score, a 6.1 point improvement in SGRQ (95% CI 3.2, 9.1), and a 45% reduction in exacerbation (RR50.55; 95%CI 0.44, 0.69) with mepolizumab as compared to placebo. CONCLUSIONS: Mepolizumab improved asthma control, QoL (measured by SGRQ) and effectively reduced exacerbations in patients with SA and comorbid upper airways disease. METHODS: We performed a descriptive, retrospective study. Patients with uncontrolled SEA treated with mepolizumab followed in the difficult to control asthma unit from Hospital La Paz were included. We entered demographic data, clinical characteristics and management of these patients in a national database. Our starting point was the visit before initiating mepolizumab, and the endpoint was the follow-up visit performed 4-6 months later. Ethical committee approval was obtained (PI-3325). RESULTS: Sixteen patients were included (median age 53.8 616.5 years old), 62.5% were female. Eight (50%) patients had allergic asthma. All patients were treated with GINA Step-5 therapy. Ten patients (62.5%) had previously received omalizumab. The rate of exacerbations after 4-6 months of treatment with mepolizumab was reduced by 91% (total exacerbations in the 12 months before mepolizumab: 44 vs after 4-6 months: 4)(p<0.001). At the second visit, the mean increase from baseline in forced expiratory volume in 1 second (FEV1) was 185 cc (p50.098). Peripheral eosinophilia was reduced by 81% after 4-6 months with mepolizumab (p<0.001). Improvement in ACT score from baseline (16.766) vs treatment (21.462.8) was 4.7 points (p50.002). Mepolizumab was suspended after an adverse event in one patient. CONCLUSIONS: Mepolizumab in our clinical practice improved asthma control, with a significant reduction in peripheral blood eosinophilia and the number of asthma exacerbations after only 4-6 months of treatment. Further long-term studies in real life are needed. RATIONALE: Omalizumab, a monoclonal anti-immunoglobulin (Ig)E antibody, approved for the treatment of moderate-to-severe persistent allergic asthma that remained uncontrolled despite high-dose inhaled corticosteroids (ICS), requiring the use of oral steroids repeatedly and emergency care. The clinical efficacy, safety and tolerability of omalizumab have been demonstrated in children aged 6 to less than 18 years.
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METHODS:
We performed a descriptive, retrospective study. Patients with uncontrolled SEA treated with mepolizumab followed in the difficult to control asthma unit from Hospital La Paz were included. We entered demographic data, clinical characteristics and management of these patients in a national database. Our starting point was the visit before initiating mepolizumab, and the endpoint was the follow-up visit performed 4-6 months later. Ethical committee approval was obtained (PI-3325). RESULTS: Sixteen patients were included (median age 53.8 616.5 years old), 62.5% were female. Eight (50%) patients had allergic asthma. All patients were treated with GINA Step-5 therapy. Ten patients (62.5%) had previously received omalizumab. The rate of exacerbations after 4-6 months of treatment with mepolizumab was reduced by 91% (total exacerbations in the 12 months before mepolizumab: 44 vs after 4-6 months: 4)(p<0.001). At the second visit, the mean increase from baseline in forced expiratory volume in 1 second (FEV1) was 185 cc (p50.098). Peripheral eosinophilia was reduced by 81% after 4-6 months with mepolizumab (p<0.001). Improvement in ACT score from baseline (16.766) vs treatment (21.462.8) was 4.7 points (p50.002). Mepolizumab was suspended after an adverse event in one patient. CONCLUSIONS: Mepolizumab in our clinical practice improved asthma control, with a significant reduction in peripheral blood eosinophilia and the number of asthma exacerbations after only 4-6 months of treatment. Further long-term studies in real life are needed. RATIONALE: Omalizumab, a monoclonal anti-immunoglobulin (Ig)E antibody, approved for the treatment of moderate-to-severe persistent allergic asthma that remained uncontrolled despite high-dose inhaled corticosteroids (ICS), requiring the use of oral steroids repeatedly and emergency care. The clinical efficacy, safety and tolerability of omalizumab have been demonstrated in children aged 6 to less than 18 years.
This was an open-label, parallel-group clinical study with subjects randomized to omalizumab performed in 12 months. We included 126 patients (6 to 17 years of age) with persistent allergic asthma and rhinitis (Total serum IgE level 75 -1500 UI/mL) who remain uncontrolled despite treatment with high doses of ICS plus a long-acting b2-agonist (LABA). Omalizumab was administered subcutaneously for 12 months. Effectiveness variables considered were change from baseline in exacerbation rate, FEV1, PEF. The quality of life related to asthma was evaluated with PAQLQ and the control with ACQ. Safety and tolerability data were also recorded. RESULTS: 91 patients remaining in the study, treatment with omalizumab group and control group. The baseline and final parameters are described for each of the treatment groups and the difference variables for each parameter (exacerbation were calculated by subtracting the final value from the baseline, in which the changes in omalizumab group are clinically better than those in control group. Asthma attacks decreased in both groups, but in omalizumab group they practically disappear with statistically significant differences. CONCLUSIONS: Add-on therapy with omalizumab significantly improved the change from baseline in FEV1, reduces exacerbations, improves control ashma and the quality of life.
